EZH2 and myelodysplastic syndrome: EZH2, the enzymatic component of PRC2 is mutated in myeloid malignancies, most commonly in MDS, chronic myelomonocytic leukemia (CMML), and primary myelofibrosis and rarely in AML (14–16).